Denagliptin has not yet been approved in the US, EU or Other Countries
Studies listed may include approved and non-approved uses, formulations or
treatment regimens. Before prescribing any product mentioned in this Register,
healthcare Professionals should consult prescribing information approved in
their country (
view UK and US information for Healthcare Professionals).
The summaries are in PDF format.
If you do not have Adobe® Acrobat® Reader™ installed, you can
download it for free.
Denagliptin studies
Select the study ID number to view the trial summary
| DPB100925 |
II |
A 12-Week, Parallel-Group, Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45mg), Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension |
